Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ALX Oncology Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALXO
Nasdaq
8731
https://alxoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ALX Oncology Holdings Inc
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
- Mar 8th, 2024 8:48 pm
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
- Mar 8th, 2024 3:41 am
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 7th, 2024 9:03 pm
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- Mar 5th, 2024 9:30 pm
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
7 Small-Cap Stocks That Wall Street Loves for Good Reason
- Dec 22nd, 2023 9:21 pm
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments
- Nov 13th, 2023 9:47 pm
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:05 pm
ALX Oncology Announces November Investor Conference Participation
- Nov 1st, 2023 8:05 pm
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Oct 10th, 2023 8:05 pm
While institutions invested in ALX Oncology Holdings Inc. (NASDAQ:ALXO) benefited from last week's 74% gain, private equity firms stood to gain the most
- Oct 9th, 2023 3:26 pm
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
- Oct 6th, 2023 8:59 am
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
- Oct 5th, 2023 2:58 pm
ALX Oncology Announces Pricing of Public Offering
- Oct 5th, 2023 12:00 pm
ALX Oncology Announces Proposed Public Offering
- Oct 4th, 2023 8:10 pm
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
- Oct 4th, 2023 3:39 pm
Why ALX Oncology Stock Is Skyrocketing Today
- Oct 3rd, 2023 3:15 pm
Midday movers: McCormick Airbnb, Point Biopharma and more
- Oct 3rd, 2023 1:36 pm
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- Oct 3rd, 2023 10:00 am
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- Oct 2nd, 2023 8:05 pm
Scroll